Do you want to read an article? Please log in or register.
PSMA radioligand therapy: State of the art
Genitourinary Cancer
APCCC 2024
Related content
COMMENTED
Genitourinary CancerNuclear Medicine
Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
★ 1
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
J Clin Med
Kınıkoğlu O, Öven BB, Çelik S, Alan Selçuk N, Beydağı G, Akçay K, Kabasakal L
doi: 10.3390/jcm13164585
COMMENTED
Nuclear Medicine
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
J Nucl Med
Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, Weber WA, Fendler WP, Hofman MS, Krause BJ, Brackman M, Kpamegan E, Ghebremariam S, Benson T, Catafau AM, Kendi AT
doi: 10.2967/jnumed.122.265077
APCCC 2024
Genitourinary Cancer
Patient selection for radioligand therapy
COMMENTED
Genitourinary CancerNuclear Medicine
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy
★ 1
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
J Nucl Med
Calais J, Morris MJ, Kendi AT, Kalebasty AR, Tutrone R, Anderson MJ, Sartor O
doi: 10.2967/jnumed.124.268363
Genitourinary Cancer
A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer
Eur Urol
Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA
doi: 10.1016/j.eururo.2024.09.020
Genitourinary Cancer
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
EJNMMI Phys
Grob D, Privé BM, Muselaers CHJ, Mehra N, Nagarajah J, Konijnenberg MW, Peters SMB
doi: 10.1186/s40658-024-00636-0
COMMENTED
Genitourinary CancerNuclear Medicine
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K, PSMAfore Investigators
doi: 10.1016/S0140-6736(24)01653-2
ASCO 2024
Genitourinary Cancer
PSMAfore: 177Lu-PSMA-617 improved time to worsening in HRQoL and pain in taxane-naïve patients with PSMA-positive mCRPC
Leukemia
Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
Leuk Lymphoma
Huntington SF, Cheng WY, Sarpong EM, Leng S, Farooqui MZH, Agu US, Catillon M, Lejeune D, Downes N, Matay L, Duh MS, De Nigris E
doi: 10.1080/10428194.2024.2331631